Multinational pharmaceutical company Novo Nordisk and Bangladesh-based Eskayef Pharmaceuticals Ltd recently signed a Memorandum of Understanding (MoU) to transfer state-of-the-art Danish insulin manufacturing technology to Bangladesh.
Anand Shetty, managing director of Novo Nordisk Bangladesh, and Simeen Hossain, managing director of Eskayef Pharmaceutical Ltd, signed the MoU on behalf of their respective organizations. State Minister for Health and Family Welfare Zahid Malik was present at the occasion as chief guest.
Danish Ambassador to Bangladesh Mikael Hemniti Winther, Novo Nordisk Oceania and South East Asia Corporate Vice-President Sebnem Avsar Tuna, and Corporate Vice-President of Finance and Operations for Novo Nordisk in Africa, Asia, Middle East and Oceania Lars Bo Smidt were present on the occaision.
Transcom Group Chairman Latifur Rahman, Directorate General of Drug Administration Director General Maj Gen Dr Md Mustafizur Rahman, Bangladesh Association of Pharmaceutical Industries General Secretary SM Shafiuzzaman, Bangladesh Investment Development Authority Executive Chairman Kazi M Aminul Islam, Diabetic Association of Bangladesh President Prof AK Azad Khan, and Ministry of Health and Family Welfare Additional Secretary Roxana Quader were also in attendance.
Novo Nordisk is a global healthcare company based in Denmark, with more than 90 years of innovation and leadership in diabetes care.